Biomarkers for Targeting the HIV-1 Reservoirs

Dong-eun Kim, Young-Hyun Shin, Cheol-Hee Yoon, Byeong-Sun Choi

Division of Chronic Viral Disease Research, Center for Emerging Virus Research, National Institute of Infectious Disease, 187 Osongsaengmyeong2-ro, Osong-yeup, Cheongju 28159, Republic of Korea

Key Words: HIV-1, HIV-1 latency, HIV-1 persistence, Viral reservoir, Biomarker

INTRODUCTION

Human immunodeficiency virus-1 (HIV-1) is a causative agent of acquired immunodeficiency syndrome (AIDS). Although highly active antiretroviral therapy (HAART) efficiently suppresses viral replication and increases the lifespan of patients, it does not completely eliminate the latently HIV-1 infected cells from a patient's body. The greatest obstacle to finding an HIV-1 cure is posed by latently infected cells, otherwise referred to as "latent viral reservoirs". Therefore, understanding the characteristics of HIV-1 reservoirs becomes a top priority in the field of HIV-1 cure research, but defining the HIV-1 reservoirs is currently limited due to a lack of definite markers for probing the latent reservoir cells which HIV-1 hides. If an assured marker for the latent reservoir cells is discovered, it will mark considerable progress in the process of understanding the characteristics and functions of HIV-1 reservoirs, and will make possible a sterilization cure by eliminating the reservoirs. In this paper, we review several cell surface molecules, including immune checkpoint molecules (PD1, TIGIT and LAG-3), CD30, CD2, CD20, CD32a, and CD127 suggested which have been as possible markers for probing HIV-1 reservoirs.
memory T cells including central memory (T_{CM}), transitional memory (T_{TM}) and effector memory T cells (T_{EM}) are known as a main subsets of reservoir for replication-competent HIV-1 (4, 12). Because the reservoirs exhibit the memory T cell properties, they mainly hide at anatomical sites such as lymphoid organs. Thus, viruses propagated from reservoirs activated in lymphoid organs rapidly spread to entire body via blood stream or cell-to-cell transmission during interruption of ART (13).

To attempt to eliminate the latent reservoirs, it is most important to determine the biomarker capable to probe the reservoirs. Thus we will overview the various biomarkers described in previous studies using latently HIV-1 infected cells and introduce ongoing research aimed at defining the latent reservoir at the Korea National Institute of Health (KNIH).

**THE LATENCY OF HIV-1 IN T-CELL SUBSETS**

As for therapeutic strategies aimed at eliminating latent HIV-1 reservoirs, it is important to understand the cell type harboring the latent HIV-1 provirus. Notably, the memory CD4 T cells known as a major reservoir, has various phenotypes according to their differentiation and memory status (9-11, 14). Fortunately, the developmental profile of memory CD4 T cell has been well conceptualized, and is best characterized as a differentiation linear model (2). HIV-1 can persist in naive (T_{N}), stem cell-like memory (T_{scm}), central (T_{CM}), transitional (T_{TM}), and effector (T_{EM}) memory CD4 T cells with different infection rates. Even though the frequency of HIV-1-infected cells is lower in T_{N} compared to T_{CM} (T_{N}: 684 vs T_{CM}: 1,279 HIV-1 DNA copies/ml, respectively), Zerbato et al. showed that T_{N} harbors highly inducible replication-competent provirus (T_{N}: 18,290 vs T_{CM}: 15,135 HIV-1 RNA copies/ml, respectively), indicating that T_{N} might not play a role as reservoir (10). Hiener et al. demonstrated that the T_{EM} of patients treated with ART contained the highest number of intact HIV-1 proviruses (14). These results provide the evidence which the frequency of intact HIV-1 proviruses differed across the T cell subtypes.

T helper type 1 cell (Th1), Th2, Th17, Th9, regulatory T cell (Treg), and follicular T helper cell (Tfh) are classified by functional polarization, and these characteristics affect the HIV-1 to be persisted (5, 15, 16). According to a recent study, proliferation of HIV-1-infected Th1 cells play a crucial role in maintaining the number of cells that harbor replication-competent HIV-1 (5). As observed in the digestive system, it was also found that T helper type 17 (Th17) cells contributed to persistence of HIV-1 in ART-treated individuals (6). Furthermore, CD4 T cells polarized to Th1/17 harbor...
A high portion of HIV-1 DNA in ART treated individuals and contribute disproportionately to the viral reservoirs remained stably during ART (15).

These studies emphasize the heterogenous natures of HIV-1 reservoirs and stress the urgent need to identify markers for latent reservoirs. If reservoirs could be isolated using a useful marker, the markers may be helpful to defining the various and complex characteristics of the reservoirs and could even make possible selective targeting for the complete eradication of the virus. So far, no cellular marker capable of distinguishing all HIV-1 reservoirs has been found; however, some HIV-1 reservoir markers have been proposed recently, and their characterization will be an important contribution to our understanding of HIV-1 reservoirs.

**IMMUNE CHECKPOINT MOLECULES (IC)**

Chronic HIV-1 infection, with its high antigen load, constantly stimulates T cells, which then brings about their dysfunction, called “T-cell exhaustion” (17, 18). During this period, the expression of several immune checkpoint molecules (ICs) increases in the T cell, which suppress the immune response, thereby increasing potential HIV-1 latent infection. These ICs include T cell immunoglobulin and immune-receptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT), programmed cell death-1 (PD-1), lymphocyte activation gene 3 (LAG-3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and mucin 3 (TIM-3), CD160, and 2B4 (CD244) (19, 20). Fromentin et al. demonstrated that TIGIT, PD-1, and LAG-3 were related to HIV-1 persistence in CD4+ T cells (19). Although differences exist depending on the subset of the memory CD4+ T cell, the majority of integrated HIV-1 DNA was found to be high in cells with at least one marker. In particular, it was observed that the level of integrated HIV-1 DNA was 8.2-fold higher in cells which expressed all three markers, compared with total CD4+ T cells (19) (Table 1). Recently, the same group reported that the ratio of HIV-1 p24 (capsid protein)-producing cells was higher in cells enriched as a single antibody panel with TIGIT, PD-1, and α4β1 (median fold 2.23, 1.65 and 2.21, respectively) using samples taken from ART patients (20).

The Perreau group reported that PD-1+/Tfh cells containing replication-competent virus in lymph node were detected highly in ART-treated aviremic HIV-1-infected individuals (21). In the follow-up study, the ratio of CXC chemokine receptor 3* (CXCR3) was found to be higher in PD-1+/Tfh memory CD4 cells (22).

IC inhibitors have already been used in cancer treatment and even been suggested as possible agents for use in HIV-1 infection cure, but their application as a treatment agent has limitations due to the inconsistent results of related clinical trials and their toxicity.

**CD30**

CD30, a member of TNF receptor superfamily, is expressed in tumor cells such as Hodgkin’s disease or aggressive lymphoma (23, 24). In particular, the rate of CD30 expression increases rapidly due to several viruses such as human T-cell lymphotropic virus and Epstein-Barr virus (25, 26). Although it has been known for twenty years that CD30 plays an important role in HIV-1 replication and HIV-1-infected CD4 T cell death (27), it was recently discovered that HIV-1 RNA is abundantly enriched in CD30+CD4+ T cells (28). In an in situ hybridization of gut-associated lymphoid tissues, the co-localization of CD30 and HIV-1 RNA was observed at 88% in the ART group and 32.5% in the viremic group. Also, after ex-vivo treatment with FDA-approved drugs (brentuximab vedotin, anti-CD30 antibody-conjugated drug) targeting CD30 in the peripheral blood mononuclear cell (PBMC) of patients, the total HIV-1 DNA was observed to decrease greatly (28).

Even though CD30 has been considered as a marker for HIV-1 replication rather than a viral persistence marker (28-30), it will be necessary to further investigate the basis for using it as an HIV-1 reservoir marker and to evaluate its possibility as a therapeutic target in a follow-up study due to lack of in vivo efficacy test yet.
CD2

CD2, a member of the immunoglobulin superfamily, is a specific marker for T cells and NK cells. Iglesias-Ussel et al. produced latently HIV-1 infected cells using an in-vitro primary CD4+ T cell model (31), and then their transcriptional activity was analyzed using the micro-array analysis. Twenty transcripts encoding cell surface proteins were up-regulated in comparison to these of uninfected cells. Of these, CD2 showed significant difference was further analyzed in patients’ samples (32). The ratio of integrated HIV-1 DNA was found to be higher in CD2high than in CD2low of the resting memory CD4 T cell (CD3+CD4+HLA-DR+CD45RA-) in the samples of ART patients, showing an increase of 5.7-fold compared to the total CD4 T cells (Table 1). In addition, viral RNA production increased in CD2high compared to CD2low, suggesting its potential as a new marker. Since it remains difficult to completely capture the latent infection reservoir, the relevance of CD2 still has to be studied in lymphoid tissues.

CD20

Although CD20 has been known as a B lymphocyte antigen initially, it is dimly expressed by CD4+ T cells of small population (1-2%) (33). Serra-Peinado et al. recently reported CD20 as a marker for HIV-1-infected CD4+ T cell. Although CD20-expressed CD4 T cells were rare, the number of cells expressed with CD20 was higher in infected cells compared to non-infected cells (34). These infected CD20+CD4+ T cells contributed medians of 18% and 25% to the total pool of HIV-1 RNA+ cells in ART-suppressed and viremic patients, respectively. Also, resting CD20+CD4+ T cells had higher levels of HIV DNA compared with the total CD4+ T cells (2.1-fold) (Table 1). In addition, ex-vivo treatment of PBMCs from ART-suppressed individuals with the anti-CD20 monoclonal antibody Rituximab appeared to greatly reduce the HIV-1 RNA+ pool. Rituximab deplete viral-reactivated cells, but it will be necessary to conduct a further study to evaluate the possible application of Rituximab as an appropriate treatment for latent infection by reducing the intact HIV DNA reservoir.

CD32a

CD32a, known as Fc gamma receptor IIa (FcγIIa), is expressed at a high level mainly in myeloid cells, and is expressed in a low rate in T cells (35, 36). Recently, Descours et al. discovered CD32a as a new marker for HIV-1 reservoir cells (37). In this paper, HIV-1 DNA was enriched by more than 1000 times with CD4+CD32a+ cells compared to CD4+CD32a- cells (Table 1). Accordingly, they demonstrated that the replication-competent provirus was enriched in CD4+CD32a+ cells. However, in the follow-up studies conducted by other groups, it was questioned whether CD32a was a real marker for HIV-1 latent reservoirs. In several papers, total HIV-1 DNA or replication-competent provirus were not enriched in CD32+ cells (38-41). The main reason for such difficult reproducibility is the technical issue that isolates CD32+CD4+ T cells with high purity. CD32+ is expressed at a much higher rate in antigen-presenting cells (APCs) compared to CD4 T cells, and if the residual APCs are not separated and left, an excessive imbalance can develop as a result (42, 43). Also, CD32b, an isoform of CD32, is highly expressed in B cells, and no antibody targeting CD32a only is present as yet; thus the technology is important for finely separating T or B cells mixed blood cells using flow cytometry (42). Very recently, Darcis et al. proved the importance of purity at the level of CD4+ T cell isolation. The results of their study showed that the interference of CD4+ T cells on CD32+ enrichment decreased as purity increased (42). Nevertheless, an additional study is needed to investigate the characterization of CD32+CD4+ cells in combination with other markers or the downstream of CD32a signaling because CD32a is related to HIV-1 infection.

CD127

Tissue memory CD4+ T cells (hereafter referred to as Tm cells) expressing IL-7 receptor-alpha (CD127) were suggested as a novel marker for latent HIV-1 reservoir (44). Previous study reported that CD127+ Tm cells were lack of productive HIV-1
HIV-1 LATENT INFECTION STUDY AT THE KNIH

At the Korea National Institute of Health, studies have been conducted to discover the factors involved in the formation and maintenance of HIV-1 infection, in the form of latent infection research mainly through epigenetics. In particular, it is thought highly possible that genes for histone modifications which commonly change in several types of latent infection cell lines, play a crucial role in HIV-1 latent infection, and a subsequent follow-up study was performed to find out that the cell-cycle regulatory genes cyclin-dependent kinase inhibitor 1 (CDKN1A) and cyclin D2 played an important
role in the maintenance of HIV-1 latent infection (46). Also, a study on the distribution of histone modifications by chromosome was performed to find out that a specific gene called nuclear factor 1 X type (NFIX) acted on the latent infection (47) (Fig. 2).

In addition, studies aimed at discovering useful HIV-1 latent infection regulatory factors and their mechanisms and finding biomarkers for detecting latent infected cells are being performed using the PBMCs from patients. The PBMCs of long-term non-progressors (LTNPs) are obtained from patients already collected and stored at the College of Medicine of the University of Ulsan, an external joint researcher, which are then subjected to RNA-Seq technique and bioinformatics integrated analysis in order to find latent infection regulatory factors and to suggest them as biomarkers for detecting latent infection (48).

**CLOSING REMARKS**

HIV-1 reservoirs exist in various ways according to heterogenous localization, longevity, and activation status (3-5, 9-11, 14, 49, 50). It is therefore reasonable to assume that various cellular proteins are highly expressed in the reservoir cell. There are conflicting views on newly suggested markers, and contradictory results have been obtained depending on the various technological issues and experimental systems, infection and preparation processes, and methods of purifying patients’ cells (37-39, 41, 43, 51-54). According to studies on recently suggested CD32a in particular, the process of isolating cells is technically important (42). Nevertheless, it was demonstrated that the expression rates of HIV-1 RNA and DNA were high in CD32a^+PD-1^-CD4^- T cells or CD32^-CD30^- cells (28, 55). At present, it is difficult to perfectly target an HIV-1 reservoir with a single surface marker, but it will eventually be possible to separate HIV-1 reservoirs with a higher rate through “multicolor” combinations of existing markers.

Finally, to understand the physiopathology of HIV-1 infection and establish appropriate treatment strategies, it is important to continue investigating the characteristics of the various T-cell subsets and non-lymphoid cells that are related to viral persistence and reactivation.

### Table 1. The surface molecules reported as biomarkers targeting HIV-1 reservoirs

| Marker | ATR | Cell Type | Outcome | Characterization & Relevance | Reference |
|--------|-----|-----------|---------|-------------------------------|-----------|
| PD-1   | 8.5 years | Memory CD4^+ T cell | Integrated HIV DNA TILDA | - PD-1^+TIGIT^-LAG^-CD4^- T cell/ total CD4^- T cell = 8.2-fold  
- PD-1^+TIGIT^- or LAG^-CD4^- T cell/ total memory CD4^- T cell = 76% inducible reservoir | (19, 20) |
| TIGIT  | 34 month | CD4^- T cell | HIV DNA qVOA | - CD32a^-/ total CD4^- T cells = 633-fold  
- CD32a^-/CD32a^-CD4^- T cells = 1024-fold  
- Population CD32a^-/ total CD4^- T cell = 26.8-86.3%  
- Population CD32a^-CD4^- T cell/ total CD4^- T cell = 3000 | (37) |
| LAG-3  | <3 years | Resting memory CD4^- T cell | HIV DNA | Most CD30^-CD4^- T cells: effector/transitional memory phenotype  
HIV RNA from CD30^-CD4^- T cells = 21%  
Population CD30^-CD4^- T cells/ total CD4^- T cell = 3.97% | (28) |
| CD32a^high | 28 month | Resting CD4^- T cell | HIV DNA | - CD2^-CD4^-/ total CD4^- T cells = 5.7 fold  
- CD2^-CD4^-/total pool HIV-expressing cells = 18.55%  
Resting CD2^-dim CD4^- T cells/ total CD4^- T cell = 2.1 fold | (34) |
| CD32a^dim | 28 month | Resting CD4^- T cell | HIV DNA | - CD2^-CD4^-/total pool HIV-expressing cells = 18.55%  
Resting CD2^-dim CD4^- T cells/ total CD4^- T cell = 2.1 fold | (34) |
ACKNOWLEDGEMENTS

This work was supported by grants from the Korea National Institute of Health (Grant Number: 2019-NI067-00).

REFERENCES

1) Kulpa DA. Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. J Virus Erad 2015;1:59-66.
2) Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory. Immunity 2018;48:214-26.
3) Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR, et al. Both CD31(+) and CD31(-) naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010;202:1738-48.
4) Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
5) Lee GQ, Orlova-Fink N, Kinkauf K, Chowdhury FZ, Sun X, Harrington S, et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest 2017;127:2689-96.
6) Gosselin A, Wiche Salinas TR, Planas D, Wacleche VS, Zhang Y, Fromentin R, et al. HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS 2015;31:35-48.
7) Pasternak AO, Berkhout B. HIV Reservoir: Finding the Right Needles in a Needlestack. Cell Host Microbe 2016;20:280-2.
8) Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 2014;20:139-42.
9) Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-7.
10) Zerbato JM, McMahon DK, Sobolewski MD, Mellors JW, Sluis-Cremer N. Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1. Clin Infect Dis 2019;69:1919-25.
11) Takeshita M, Suzuki K, Kassai Y, Takiguchi M, Nakayama Y, Otomo Y, et al. Polarization diversity of human CD4+ stem cell memory T cells. Clin Immunol 2015;159:107-17.
12) Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004;78:1160-8.
13) Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV reservoirs. Rev Med Virol 2017;27.
14) Hiener B, Horsburgh BA, Eden JS, Barton K, Schlub TE, Lee E, et al. Identification of Genetically Intact HIV-1 Proviruses in Specific CD4(+) T Cells from Effectively Treated Participants. Cell Rep 2017;21:813-22.
15) Sun H, Kim D, Li X, Kiselinova M, Ouyang Z, Vandekerckhove L, et al. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. J Virol 2015;89:11284-93.
16) Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013;121:2402-14.
17) Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9.
18) Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, et al. TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog 2016;12:e1005349.
19) Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. *PLoS Pathog* 2016;12:e1005761.

20) Pardons M, Baxter AE, Massanella M, Pagliuza A, Fromentin R, Dufour C, et al. Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. *PLoS Pathog* 2019;15:e1007619.

21) Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. *J Exp Med* 2013;210:143-56.

22) Banga R, Procopio FA, Ruggiero A, Noto A, Ohmiti K, Cavassini M, et al. Blood CXCR3(+) CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals. *Front Immunol* 2018;9:144.

23) Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood* 1985;66:848-58.

24) Falini B, Pileri S, Pizzolo G, Dirikop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. *Blood* 1995;85:1-14.

25) Makino M, Yashiki S, Fujiyoshi T, Baba M, Sonoda S. An expression of anaplastic large cell lymphoma-associated antigens on HTLV-I-infected CD4+ T cells. *Ann Hematol* 1998;76:31-5.

26) Higuchi M, Matsuda T, Mori N, Yamada Y, Horie R, Watanabe T, et al. Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. *Retrovirology* 2005;2:29.

27) Romagnani S, Annunziato F, Manetti R, Almerigogna F, Biagiotti R, Giudizi MG, et al. Role for CD30 in HIV expression. *Immunol Lett* 1996;51:83-8.

28) Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriquez B, Hussien R, et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. *PLoS Pathog* 2018;14:e1006856.

29) Wang CC, Thanh C, Gibson EA, Ball-Burack M, Hogan LE, Descours B, et al. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. *Blood Adv* 2018;2:3479-82.

30) Romagnani S. Th1 and Th2 in human diseases. *Clin Immunol Immunopathol* 1996;80:225-35.

31) Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. *J Immunol* 2008;181:7713-20.

32) Iglesias-Ussel M, Vandergeeten C, Marchionni L, Chomont N, Romerio F. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. *J Virol* 2013;87:9148-58.

33) Henry C, Ramadan A, Montcuquet N, Pallandre JR, Mercier-Letondal P, Deschamps M, et al. CD3+CD20+ cells may be an artifact of flow cytometry: comment on the article by Wilk et al. *Arthritis Rheum* 2010;62:2561-3; author reply 3-5.

34) Serra-Peinado C, Grau-Expósito J, Luque-Ballesteros L, Astorga-Gamaza A, Navarro J, Gallego-Rodriguez J, et al. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. *Nat Commun* 2019;10:3705.

35) Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. *Nat Rev Drug Discov* 2012;11:311-31.

36) Holgado MP, Sananez I, Raiden S, Geffner JR, Arruvito L. CD32 Ligation Promotes the Activation of CD4(+) T Cells. *Front Immunol* 2018;9:2814.
37) Descours B, Petitjean G, López-Zaragoza JL, Bruel T, Raffel R, Psomas C, et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. *Nature* 2017;543:564-7.

38) Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito I, Spivak AM, Nell RA, Tomescu C, et al. CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. *Sci Transl Med* 2018;10:eaar6759.

39) Pérez L, Anderson J, Chipman J, Thorkelson A, Chun TW, Moir S, et al. Conflicting evidence for HIV enrichment in CD32(+) CD4 T cells. *Nature* 2018;561:E9-E16.

40) Bertagnolli LN, White JA, Simonetti FR, Beg SA, Lai J, Tomescu C, et al. The role of CD32 during HIV-1 infection. *Nature* 2018;561:E17-E9.

41) Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, et al. Evidence that CD32a does not mark the HIV-1 latent reservoir. *Nature* 2018;561:E20-E8.

42) Darcis G, Berkhout B, Pasternak AO. The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like. *Front Immunol* 2019;10:2251.

43) Martin GE, Pace M, Thornhill JP, Phetsouphanh C, Meyerowitz J, Gossez M, et al. CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. *Front Immunol* 2018;9:928.

44) Hsiao F, Frouard J, Gramatica A, Xie G, Telwatte S, Lee GQ, et al. Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection. *PLoS Pathog* 2020;16:e1008450.

45) Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, et al. Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. *Cell Rep* 2017;20:984-98.

46) Park J, Lim CH, Ham S, Kim SS, Choi BS, Roh TY. Genome-wide analysis of histone modifications in latently HIV-1 infected T cells. *AIDS* 2014;28:1719-28.

47) Kim KC, Lee S, Son J, Shin Y, Yoon CH, Kang C, et al. Identification of novel genes associated with HIV-1 latency by analysis of histone modifications. *Hum Genomics* 2017;11:9.

48) Lee SY, Park YK, Yoon CH, Kim K, Kim KC. Meta-analysis of gene expression profiles in long-term non-progressors infected with HIV-1. *BMC Med Genomics* 2019;12:3.

49) Lee GQ, Lichterfeld M. Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. *Curr Opin HIV AIDS* 2016;11:383-7.

50) Khoury G, Anderson JL, Fromentin R, Hartogenesis W, Smith MZ, Bacchetti P, et al. Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. *AIDS* 2016;30:1511-20.

51) Badia R, Ballana E, Castellvi M, Garcia-Vidal E, Pujantell M, Clotet B, et al. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. *Nat Commun* 2018;9:2739.

52) Darcis G, Kootstra NA, Hooibrink B, van Montfort T, Maurer I, Groen K, et al. CD32(+)/CD4(+) T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency. *Cell Rep* 2020;30:2284-96. e3.

53) Thornhill JP, Pace M, Martin GE, Hoare J, Peake S, Herrera C, et al. CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype. *Mucosal Immunol* 2019;12:1212-9.

54) Wittner M, Dunay GA, Kummer S, Bockhorn M, Hifner A, Schmiedel S, et al. CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation. *J Acquir Immune Defic Syndr* 2018;77:345-9.

55) Noto A, Procopio FA, Banga R, Suffiotti M, Corpataux JM, Cavassini M, et al. CD32(+) and PD-1(+) Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. *J Virol* 2018;92:e00901-18.